{"preliminary_commentary":{"by_channel":{"x_thread":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"ACTengine","nct_id":"NCT03686124","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=actengine-nct03686124. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ACTengine","arms":[{"description":"Dose escalation of IMA203","label":"Dose Escalation A (closed to enrollment)","type":"EXPERIMENTAL"},{"description":"IMA203 at RP2D","label":"Extension Cohort A","type":"EXPERIMENTAL"},{"description":"IMA203 at RP2D + nivolumab","label":"Extension Cohort B (closed to enrollment)","type":"EXPERIMENTAL"},{"description":"IMA203 at final RP2D (flat dose)","label":"Extension Cohort AA","type":"EXPERIMENTAL"},{"description":"IMA203 at RP2D","label":"Uveal Melanoma","type":"EXPERIMENTAL"},{"description":"Dose escalation of IMA203CD8","label":"Dose Escalation B","type":"EXPERIMENTAL"},{"description":"IMA203CD8 at dose levels confirmed to be safe","label":"Extension Cohort C","type":"EXPERIMENTAL"},{"description":"IMA203CD8 at dose levels confirmed to be safe; without IL-2","label":"Extension Cohort D","type":"EXPERIMENTAL"},{"description":"IMA203CD8 monotherapy at dose levels confirmed to be safe","label":"Ovarian","type":"EXPERIMENTAL"},{"description":"IMA203CD8 monotherapy at dose levels confirmed to be safe","label":"Endometrial","type":"EXPERIMENTAL"},{"description":"IMA203CD8 monotherapy at dose levels confirmed to be safe","label":"Head and Neck, Lung, and Triple Negative Breast Cancer","type":"EXPERIMENTAL"},{"description":"IMA203CD8 monotherapy at dose levels confirmed to be safe","label":"Rare Cancers","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2032-06","type":"ESTIMATED"},"conditions":["Refractory Cancer","Recurrent Cancer","Solid Tumor, Adult","Cancer"],"enrollment":{"count":375,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"IMA203 Product","otherNames":["anzutresgene autoleucel","anzu-cel"],"type":"BIOLOGICAL"},{"name":"IMA203 product- flat dose","otherNames":["anzutresgene autoleucel","anzu-cel"],"type":"BIOLOGICAL"},{"name":"IMA203CD8 Product","otherNames":[],"type":"BIOLOGICAL"},{"name":"Nivolumab","otherNames":["Opdivo®"],"type":"DRUG"},{"name":"IMADetect®","otherNames":[],"type":"DEVICE"}],"last_update":"2026-05-13","lead_sponsor":"Immatics US, Inc.","official_title":"Phase 1/2 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2028-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Phase 1: Determine the MTD and/or recommended dose for extension for IMA203/IMA203CD8","timeFrame":"28 days"},{"measure":"Phase 1 and Phase 2: Number and grade of treatment emergent adverse events and adverse events of special interest in subjects treated.","timeFrame":"35 days"},{"measure":"Phase 1 and Phase 2: Tumor Response","timeFrame":"5 years"}],"references":[{"citation":"Wermke M, Araujo DM, Chatterjee M, Tsimberidou AM, Holderried TAW, Jazaeri AA, Reshef R, Bokemeyer C, Alsdorf W, Wetzko K, Brossart P, Aslan K, Backert L, Bunk S, Fritsche J, Gulde S, Hengler S, Hilf N, Hossain MB, Hukelmann J, Kalra M, Krishna D, Kursunel MA, Maurer D, Mayer-Mokler A, Mendrzyk R, Mohamed A, Pozo K, Satelli A, Letizia M, Schuster H, Schoor O, Wagner C, Rammensee HG, Reinhardt C, Singh-Jasuja H, Walter S, Weinschenk T, Luke JJ, Britten CM. Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial. Nat Med. 2025 Jul;31(7):2365-2374. doi: 10.1038/s41591-025-03650-6. Epub 2025 Apr 9.","pmid":"40205198","type":"DERIVED"}],"start_date":{"date":"2019-05-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors","url":"https://clinicaltrials.gov/study/NCT03686124"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/actengine-nct03686124"}